For patients with type 2 diabetes, prediabetes, or metabolic syndrome, treatment decisions should be based on medical history, laboratory results, current medications, and established clinical guidelines
This also adds to the ability to lose weight, also because of the slower gastric emptying
Human studies show more modest improvements, reflecting important species differences in nasal permeability
Tirzepatide has shown the largest results so far, with average reductions ranging from 15% to nearly 21% over 72 weeks, depending on dose
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily licensed in the UK for managing type 2 diabetes mellitus and, in some cases, obesity